RIFAXIMIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C43H51N3O11
Molecular Weight	785.8785
Optical Activity	UNSPECIFIED
Defined Stereocenters	9 / 9
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C4=C(C(O)=C3C)C(O)=C(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C5=C4N=C6C=C(C)C=CN56

InChI

InChIKey=NZCRJKRKKOLAOJ-XRCRFVBUSA-N

InChI=1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37(50)25(7)40-31(29)41(52)43(9,57-40)55-17-15-27(54-10)22(4)39(56-26(8)47)24(6)36(49)23(5)35(48)20(2)12-11-13-21(3)42(53)45-33(34(32)46)38(30)51/h11-18,20,22-24,27,35-36,39,48-51H,1-10H3,(H,45,53)/b12-11+,17-15+,21-13-/t20-,22+,23+,24+,27-,35-,36+,39+,43-/m0/s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021361s012lbledt.pdf
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/cdi/rifaximin.html http://www.rxlist.com/xifaxan-drug.htm http://www.wikidoc.org/index.php/Special:Search?search=RIFAXIMIN

Rifaximin is a structural analog of rifampin and a non-systemic, gastrointestinal site-specific antibiotic. Rifaximin acts by inhibiting bacterial ribonucleic acid (RNA) synthesis and contributes to restore intestinal microflora imbalance. It is FDA approved for the treatment of travelers’ diarrhea, reduction in risk of overt hepatic encephalopathy (HE) recurrence and treatment of irritable bowel syndrome with diarrhea. More common side effects are: black, tarry stools; dizziness or lightheadedness; muscle spasm; rapid breathing; shortness of breath; trouble sleeping. Co-administration of cyclosporine, with XIFAXAN resulted in 83-fold and 124-fold increases in rifaximin mean Cmax in healthy subjects.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Cytochrome P450 3A4 127 Target ID: CHEMBL340 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021361s012lbledt.pdf	Inhibitor 8297	25.0 µM [IC50]
Pregnane X receptor 35 Target ID: CHEMBL3401 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17442842	Activator 1430
DNA-directed RNA polymerase subunit beta 5 Target ID: P0A8V2 Gene ID: 948488.0 Gene Symbol: rpoB Target Organism: Escherichia coli (strain K12) Sources: https://www.ncbi.nlm.nih.gov/pubmed/16096056	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Travelers’ diarrhea 7 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021361s012lbledt.pdf	Curative	Approved 8429	XIFAXAN Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of XIFAXAN and other antibacterial drugs, XIFAXAN when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. XIFAXAN is a rifamycin antibacterial indicated for: The treatment of patients (≥ 12 years of age) with travelers’ diarrhea (TD) caused by noninvasive strains of ( ) Escherichia coli 1.1 Reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥ 18 years of age ( ) 1.2 Limitations of Use TD: Do not use in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than ( ) Escherichia coli 1.1 1.1 Travelers’ Diarrhea XIFAXAN 200 mg is indicated for the treatment of patients (≥ 12 years of age) with travelers’ diarrhea caused by noninvasive strains of Escherichia coli [see Warnings and Precautions ( ), Clinical Pharmacology ( ) and Clinical Studies ( ) Launch Date 2004
Overt hepatic encephalopathy recurrence 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021361s012lbledt.pdf	Preventing	Approved 8429	XIFAXAN Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of XIFAXAN and other antibacterial drugs, XIFAXAN when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. XIFAXAN is a rifamycin antibacterial indicated for: The treatment of patients (≥ 12 years of age) with travelers’ diarrhea (TD) caused by noninvasive strains of ( ) Escherichia coli 1.1 Reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥ 18 years of age ( ) 1.2 Limitations of Use TD: Do not use in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than ( ) Escherichia coli 1.1 1.1 Travelers’ Diarrhea XIFAXAN 200 mg is indicated for the treatment of patients (≥ 12 years of age) with travelers’ diarrhea caused by noninvasive strains of Escherichia coli [see Warnings and Precautions ( ), Clinical Pharmacology ( ) and Clinical Studies ( ) Launch Date 2004
Irritable bowel syndrome with diarrhea 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021361s012lbledt.pdf	Primary	Approved 8429	XIFAXAN Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of XIFAXAN and other antibacterial drugs, XIFAXAN when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. XIFAXAN is a rifamycin antibacterial indicated for: The treatment of patients (≥ 12 years of age) with travelers’ diarrhea (TD) caused by noninvasive strains of ( ) Escherichia coli 1.1 Reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥ 18 years of age ( ) 1.2 Limitations of Use TD: Do not use in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than ( ) Escherichia coli 1.1 1.1 Travelers’ Diarrhea XIFAXAN 200 mg is indicated for the treatment of patients (≥ 12 years of age) with travelers’ diarrhea caused by noninvasive strains of Escherichia coli [see Warnings and Precautions ( ), Clinical Pharmacology ( ) and Clinical Studies ( ) Launch Date 2004

C_max

Value	Dose	Analyte	Population
4.1 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf	550 mg single, oral dose: 550 mg route of administration: Oral experiment type: SINGLE co-administered:	RIFAXIMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
3.4 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf	550 mg 2 times / day steady-state, oral dose: 550 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	RIFAXIMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
4.8 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf	550 mg single, oral dose: 550 mg route of administration: Oral experiment type: SINGLE co-administered:	RIFAXIMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED

AUC

Value	Dose	Analyte	Population
11.1 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf	550 mg single, oral dose: 550 mg route of administration: Oral experiment type: SINGLE co-administered:	RIFAXIMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
12.3 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf	550 mg 2 times / day steady-state, oral dose: 550 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	RIFAXIMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
22.5 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf	550 mg single, oral dose: 550 mg route of administration: Oral experiment type: SINGLE co-administered:	RIFAXIMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.8 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf	550 mg single, oral dose: 550 mg route of administration: Oral experiment type: SINGLE co-administered:		RIFAXIMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
4.8 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf	550 mg single, oral dose: 550 mg route of administration: Oral experiment type: SINGLE co-administered:		RIFAXIMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
32.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf	550 mg single, oral dose: 550 mg route of administration: Oral experiment type: SINGLE co-administered:		RIFAXIMIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

Doses

Dose	Population	Adverse events
200 mg 3 times / day multiple, oral Recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf Page: p.4	unhealthy, 18-79 n = 320 Health Status: unhealthy Condition: Travelers’ diarrhea caused by noninvasive strains of Escherichia coli Age Group: 18-79 Sex: M+F Population Size: 320 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf Page: p.4	Disc. AE: Taste loss, Dysentery... AEs leading to discontinuation/dose reduction: Taste loss Dysentery Weight decrease Anorexia Nausea Nasal passage irritation Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf Page: p.4
1200 mg 2 times / day multiple, oral Highest studied dose Dose: 1200 mg, 2 times / day Route: oral Route: multiple Dose: 1200 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22155172 Page: p.478	unhealthy, 18–73 n = 99 Health Status: unhealthy Condition: Crohn's disease Age Group: 18–73 Sex: M+F Population Size: 99 Sources: https://pubmed.ncbi.nlm.nih.gov/22155172 Page: p.478	Sources: https://pubmed.ncbi.nlm.nih.gov/22155172 Page: p.478
800 mg 3 times / day multiple, oral Highest studied dose Dose: 800 mg, 3 times / day Route: oral Route: multiple Dose: 800 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10741936 Page: p.207	unhealthy, 32-82 n = 17 Health Status: unhealthy Condition: Hepatic Encephalopathy Age Group: 32-82 Sex: M+F Population Size: 17 Sources: https://pubmed.ncbi.nlm.nih.gov/10741936 Page: p.207	Sources: https://pubmed.ncbi.nlm.nih.gov/10741936 Page: p.207
550 mg 3 times / day multiple, oral Studied dose Dose: 550 mg, 3 times / day Route: oral Route: multiple Dose: 550 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27528177 Page: p.1119	unhealthy, 46.4 n = 2579 Health Status: unhealthy Condition: Diarrhea-Predominant Irritable Bowel Syndrome Age Group: 46.4 Sex: M+F Population Size: 2579 Sources: https://pubmed.ncbi.nlm.nih.gov/27528177 Page: p.1119	Sources: https://pubmed.ncbi.nlm.nih.gov/27528177 Page: p.1119

AEs

AE	Significance	Dose	Population
Anorexia	Disc. AE	200 mg 3 times / day multiple, oral Recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf Page: p.4	unhealthy, 18-79 n = 320 Health Status: unhealthy Condition: Travelers’ diarrhea caused by noninvasive strains of Escherichia coli Age Group: 18-79 Sex: M+F Population Size: 320 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf Page: p.4
Dysentery	Disc. AE	200 mg 3 times / day multiple, oral Recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf Page: p.4	unhealthy, 18-79 n = 320 Health Status: unhealthy Condition: Travelers’ diarrhea caused by noninvasive strains of Escherichia coli Age Group: 18-79 Sex: M+F Population Size: 320 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf Page: p.4
Nasal passage irritation	Disc. AE	200 mg 3 times / day multiple, oral Recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf Page: p.4	unhealthy, 18-79 n = 320 Health Status: unhealthy Condition: Travelers’ diarrhea caused by noninvasive strains of Escherichia coli Age Group: 18-79 Sex: M+F Population Size: 320 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf Page: p.4
Nausea	Disc. AE	200 mg 3 times / day multiple, oral Recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf Page: p.4	unhealthy, 18-79 n = 320 Health Status: unhealthy Condition: Travelers’ diarrhea caused by noninvasive strains of Escherichia coli Age Group: 18-79 Sex: M+F Population Size: 320 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf Page: p.4
Taste loss	Disc. AE	200 mg 3 times / day multiple, oral Recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf Page: p.4	unhealthy, 18-79 n = 320 Health Status: unhealthy Condition: Travelers’ diarrhea caused by noninvasive strains of Escherichia coli Age Group: 18-79 Sex: M+F Population Size: 320 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf Page: p.4
Weight decrease	Disc. AE	200 mg 3 times / day multiple, oral Recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf Page: p.4	unhealthy, 18-79 n = 320 Health Status: unhealthy Condition: Travelers’ diarrhea caused by noninvasive strains of Escherichia coli Age Group: 18-79 Sex: M+F Population Size: 320 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf Page: p.4

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587 inducer 781	inhibitor 1767	inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1461 CYP1A2 1524 CYP2A6 707 CYP2B6 810 CYP2C19 1478 CYP2E1 882	P-gp 1537

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022554Orig1s000ClinPharmR.pdf#page=23 Page: 23,30	likely
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022554Orig1s000ClinPharmR.pdf#page=30 Page: 30.0	no
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022554Orig1s000ClinPharmR.pdf#page=30 Page: 30.0	no
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022554Orig1s000ClinPharmR.pdf#page=30 Page: 30.0	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022554Orig1s000ClinPharmR.pdf#page=30 Page: 30.0	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022554Orig1s000ClinPharmR.pdf#page=30 Page: 30.0	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022554Orig1s000ClinPharmR.pdf#page=30 Page: 30.0	no
CYP2E1 970	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022554Orig1s000ClinPharmR.pdf#page=30 Page: 30.0	no
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022554Orig1s000ClinPharmR.pdf#page=30 Page: 30.0	no
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022554Orig1s000ClinPharmR.pdf#page=30 Page: 30.0	yes	weak (co-administration study) Comment: Mean AUC of midazolam was 3.8% and 8.8% lower, respectively, after rifaximin was administered 3x a day for 7 days and 14 days, respectively. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022554Orig1s000ClinPharmR.pdf#page=30 Page: 30.0

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022554Orig1s000ClinPharmR.pdf#page=23 Page: 23,30	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022554Orig1s000PharmR.pdf#page=9 Page: 9.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:75246	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:75246
ChemicalBook	CB5244184	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5244184
MolPort	MolPort-003-850-182	https://www.molport.com/shop/molecule-link/MolPort-003-850-182
MolPort	MolPort-046-416-955	https://www.molport.com/shop/molecule-link/MolPort-046-416-955
Selleck Chemicals	Rifaximin(Xifaxan)	http://www.selleckchem.com/products/Rifaximin(Xifaxan).html
ZINC	ZINC000169621200	http://zinc15.docking.org/substances/ZINC000169621200
eMolecules	26943529	https://www.emolecules.com/cgi-bin/more?vid=26943529
eMolecules	29781310	https://www.emolecules.com/cgi-bin/more?vid=29781310
eMolecules	30154455	https://www.emolecules.com/cgi-bin/more?vid=30154455
eMolecules	31590059	https://www.emolecules.com/cgi-bin/more?vid=31590059
eMolecules	32278142	https://www.emolecules.com/cgi-bin/more?vid=32278142

PubMed

Title	Date	PubMed
Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.	1995 Mar	7774516
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.	2001 Nov	11792017
Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety.	2005	15976747
Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.	2005	15855748
Rifaximin: a new treatment for travelers' diarrhea.	2005 Feb	15598963
Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic.	2006	16498249
Rifaximin for the treatment of hepatic encephalopathy.	2008 Aug	18657018
Systematic review: prevention of travellers' diarrhoea.	2008 May	18284650
The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea.	2009	19898648
Rifaximin pharmacology and clinical implications.	2009 Jun	19442033
Review of rifaximin as treatment for SIBO and IBS.	2009 Mar	19243285
Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.	2010 Jan	19881343
Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections.	2010 Jul	20586560
Pharmacotherapy of hepatic encephalopathy in cirrhosis.	2010 Jun	20384539
Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers' diarrhoea.	2010 Jun	20331580
Rifaximin in hepatic encephalopathy: more than just a non-absorbable antibiotic?	2010 Sep	20561708
Solomonsterols A and B from Theonella swinhoei. The first example of C-24 and C-23 sulfated sterols from a marine source endowed with a PXR agonistic activity.	2011 Jan 13	21141967
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity.	2011 Jul 14	21599020
Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis.	2012	22291955
Chronic exposure to rifaximin causes hepatic steatosis in pregnane X receptor-humanized mice.	2012 Oct	22790967

Patents

Sample Use Guides

In Vivo Use Guide

Travelers’ Diarrhea: The recommended dose is one 200 mg tablet taken orally three times a day for 3 days. Hepatic Encephalopathy: The recommended dose is one 550 mg tablet taken orally two times a day. Irritable Bowel Syndrome with Diarrhea: The recommended dose is one 550 mg tablet taken orally three times a day for 14 days. It can be taken with or without food.

Route of Administration: Oral

In Vitro Use Guide

The activities of rifaximin against enteropathogens were found to be as follows: a MIC50 of 4 to 8 μg/ml and a MIC90 of >8 μg/ml.

Name

Type

Language

RIFAXIMIN

Official Name

English

(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-25-(ACETYLOXY)-5,6,21,23-TETRAHYDROXY-27-METHOXY-2,4,11,16,20,22,24,26-OCTAMETHYL-2,7-(EPOXYPENTADECA(1,11,13)TRIENIMINO)BENZOFURO(4,5-E)PYRIDO(1,2-A)BENZIMIDAZOLE-1,15(2H)-DIONE

Common Name

English

RIFAXIMIN [USAN]

Common Name

English

rifaximin [INN]

Common Name

English

NSC-758957

Code

English

RIFAXIMIN [VANDF]

Common Name

English

RIFAXIMIN [EP IMPURITY]

Common Name

English

RIFAXIMIN [ORANGE BOOK]

Common Name

English

RIFAMYCIN L 105

Common Name

English

RIFAXIDIN

Common Name

English

L-105

Common Name

English

RIFAXIMIN [EP MONOGRAPH]

Common Name

English

Rifaximin [WHO-DD]

Common Name

English

RIFAXIMIN [MART.]

Common Name

English

RIFAXIMIN [MI]

Common Name

English

XIFAXSAN

Brand Name

English

2,7-(EPOXYPENTADECA(1,11,13)TRIENIMINO)BENZOFURO(4,5-E)PYRIDO(1,2-A)BENZIMIDAZOLE-1,15(2H)-DIONE, 25-(ACETYLOXY)-5,6,21,23-TETRAHYDROXY-27-METHOXY-2,4,11,16,20,22,24,26-OCTAMETHYL-, (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-

Systematic Name

English

RIFAXIMIN [JAN]

Common Name

English

4-DEOXY-4'-METHYLPYRIDO(1',2'-1,2)IMIDAZO(5,4-C)RIFAMYCIN SV

Common Name

English

Classification Tree Code System Code

WHO-ATC

D06AX11